Microsoft Unveils Massive Global AI Investments, Prioritizing India’s Rapidly Growing Digital Market 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Trump’s Approval of AI Chip Sales to China Triggers Bipartisan National Security Concerns 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
Gulf Sovereign Funds Unite in Paramount–Skydance Bid for Warner Bros Discovery 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
GameStop Misses Q3 Revenue Estimates as Digital Shift Pressures Growth 
Samsung SDI Secures Major LFP Battery Supply Deal in the U.S. 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
BOSTON, Nov. 03, 2016 -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced it will webcast its corporate presentation at the Stifel 2016 Healthcare Conference on Tuesday, November 15 at 1:30 p.m. Eastern Time.
A live audio webcast of the presentation will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under “webcasts and presentations.” An archived version of the webcast will be available for at least 15 days following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, with headquarters in Boston, is focused on bringing innovative medicines to people with renal disease. In December 2014, the company launched its first FDA-approved medicine, Auryxia® (ferric citrate) in the United States. In January 2014, ferric citrate was approved for use in Japan, where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex). For more information about Keryx, please visit www.keryx.com.
KERYX BIOPHARMACEUTICALS CONTACT: Lora Pike Senior Director, Investor Relations T: 617-466-3511 [email protected]
